CTOs on the Move

Huyabio

www.huyabio.com

 
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.huyabio.com
  • 12531 High Bluff Drive Suite 138
    San Diego, CA USA 92130
  • Phone: 858.798.8800

Executives

Name Title Contact Details

Similar Companies

UltraFiltronics Corp

UltraFiltronics Corp is a Randolph, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BCY LifeSciences

BCY LifeSciences Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PetMed

PetMeds® is America`s Largest Pet Pharmacy, a publicly traded company (NASDAQ: PETS). We deliver prescription and non-prescription pet meds along with health and nutritional supplements for dogs, cats and horses at substantial savings directly to you. We serve millions of satisfied customers nationwide from one location.

Pharmacyvillage.com

Pharmacyvillage.com is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.